M E van der Burg

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

Elizabeth A. Eisenhauer, W.W. ten Bokkel Huinink, Kenneth D. Swenerton et al. · Journal of Clinical Oncology · 1994 · 640 citations

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

J.P. Neijt, W W ten Bokkel Huinink, M E van der Burg et al. · Journal of Clinical Oncology · 1987 · 312 citations

Urology, Cp Treatment, Medicine +15

A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.

P J van Diest, Peter A. van Dam, S.C. Henzen‐Logmans et al. · Journal of Clinical Pathology · 1997 · 199 citations · Full text

Tumor Biology, Prognostic Biomarkers, Tumoral Pathology +14

A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)

Gordon Rustin, M E van der Burg · Journal of Clinical Oncology · 2009 · 101 citations

Surgical Oncology, Cancer Management, Gynecology +19

Predictability of the survival of patients with advanced ovarian cancer.

Hans C. van Houwelingen, W.W. ten Bokkel Huinink, M E van der Burg et al. · Journal of Clinical Oncology · 1989 · 88 citations

Prognostic Evaluation, Urology, Advanced Ovarian Cancer +14